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Role of proteoglycans and cytoskeleton in the effects of TGF-/31 on
renal function. Transforming growth factor-beta (TGF-/3) is a critical
cell regulatory protein which influences cell growth, cell differentiation
and cell chemotaxis. TGF-/3l has been previously shown to promote a
migratory and adherent transformation of monolayers of renal proximal
tubule cells in primary culture to form solid clusters of cells. To better
understand the cellular basis of this TGF-131 effect, these studies
evaluated the influence of TGF-/31 on the synthesis of proteoglycans
and on cytoskeleton rearrangement in rabbit renal proximal tubule cells
in primary culture, and their role in this transformation effect of
TGF-/31. Biosynthetic labeling of proteoglycans with 35S sulfate and
enzyme digestion studies demonstrated that TGF-f3l promoted the
synthesis of heparan sulfate proteoglycans in these cells. The impor-
tance of proteoglycan synthesis induced by TGF-/3l in this migration
and aggregation process was demonstrated with the use of two chemi-
cally-dissimilar proteoglycan synthesis inhibitors: xyloside and galac-
tosamine. Both compounds inhibited TGF-/3l stimulation of proteogly-
can synthesis and diminished TGF-131 promoted transformation of
proximal tubule cells as assessed by quantitative morphometry. Further
experiments evaluated the influence of TGF-f3l on actin microfilaments
with the use of rhodamine conjugated phalloidin staining and immuno-
fluorescent microscopy, and demonstrated that TGF-/3l provoked a
dramatic rearrangement of actin microfilaments into stress fibers. The
use of actin microfilament disrupting agents, cytochalasin B and D,
attenuated the stress fiber formation promoted by TGF-13l and inhibited
the TGF-/3l-induced morphologic transformation of these cells. Further
studies evaluated these effects on the rate of DNA synthesis in these
cells, as assessed with 3H-thymidine incorporation. Proteoglycan syn-
thesis inhibitors significantly diminished the maximal proliferative
response of these epithelial cells to epidermal growth factor (EGF). In
contrast, actin microfilament disaggregation with cytochalasin B or D
did not change the rate of DNA synthesis in response to EGF but did
attenuate the antiproliferative effect of TGF-/3l on EGF-induced DNA
synthesis cells. These studies demonstrate that the TGF-/3l promoted
an increase in the production of proteoglycans and a higher ordered
structure of the cytoskeleton. Both effects were instrumental in the
adhesive migratory response of proximal tubule cells to TGF-/3l as well
as the DNA synthesis rate response to both EGF and TGF-f31.
Transforming growth factor-beta (TGF-f3) consists of a family
of polypeptides with multiple functions in growth and differen-
tiation [1—3]. To date, three mammalian isoforms have been
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identified: TGF-f31, 132, and /33. An impressive feature of this
family of regulatory polypeptides is its multifunctionality. De-
pending on the cell type and cell environment, TGF-beta
polypeptides can act as differentiating or proliferating factors
[4—7]. Accordingly, this family of regulatory polypeptides has
been demonstrated to be important in embryonic morphogene-
sis [8, 9], wound healing [10] and inflammatory processes [11,
12].
Recent observations have demonstrated that TGF-/31 has
dramatic effects on renal proximal tubule cells in primary cell
culture to alter growth responses under both basal and growth
stimulating conditions [13—15]. In addition, TGF-/31 promoted a
dramatic phenotypic alteration of the epithelial monolayer to
transform into solid clusters of adherent cells [14], a process
highly reminiscent to the initial inductive step of tubulogenesis
in embryonic kidney morphogenesis [16].
To further understand the cellular basis of the TGF-/31
promoted effects on renal proximal tubule cells, the present
series of experiments were undertaken. Since TGF-f3 has a
dramatic effect on extracellular matrix production [17, 18], the
effect of TGF-/31 on proteoglycan and fibronectin synthesis by
renal proximal tubule cells and the functional role of these
matrix components on the observed responses to TGF-f31 were
evaluated. Since one of the effects of TGF-f31 is also character-
ized not only by increased cell adhesion but also by cell
migration, the effect of TGF-f31 on cytoskeletal rearrangement
in renal tubule cells and the functional role of microfilament
aggregation on this TGF-/31 promoted processes were also
assessed. The results of these experiments do, indeed, suggest
an important role for proteoglycan synthesis and cytoskeletal




Rabbit renal proximal tubule cells were grown in primary
culture by previously reported techniques [14]. The cells were
grown in 35 mm. Corning culture dishes with serum free,
hormonally defined DME, Hams F-l2 media (1:1, vol/vol)
containing glutamine, penicillin, streptomycin, 50 flM hydrocor-
tisone, 5 g/ml insulin, and 5 sg/ml transferrin. The cultures
were maintained in a humidified 5% C02/95% air incubator at
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37°C. Media were changed every three to five days. Cultures
became confluent in 9 to 12 days.
Biosynthetic labeling
Cultures were grown to confluence and were made quiescent
by the addition of fresh medium containing no hydrocortisone
and insulin and with low sulfate content for 35S-sulfate labeling
studies or with low methionine content for 35S-methionine
labeling. Cells were pretreated with 4-methylumbel1ifery1-3-D-
xyloside (xyloside, 1 mM), galactosamine (2.5 mM) or sham
solution for 6 to 24 hours at which time TGF-/31 (10 nglml) was
added. Cells were then exposed to TGF-f31 for 48 hours. This
dose and exposure time were chosen after preliminary data
demonstrated that these were maximal and optimal in assessing
the measured parameters. Furthermore, under these condi-
tions, TGF-j31 did not change cell numbers in the confluent
plates. Eighteen hours prior to the termination of the experi-
ment, 55S-sulfate (200 CiIml) or 35S-methionine (150 sCiJml)
was added to the cultures. Culture media and cell layers were
harvested and processed for SDS-PAGE with fluorography as
previously described [18]. Proteoglycans were identified by
enzyme digestion and matrix proteins by immunoprecipitation
as previously reported [18, 19]. Enzymatic digestion to identify
proteoglycans was performed on conditioned media after bio-
synthetic labeling. Aliquots of medium (25 sl) were mixed with
100 milliunits of chondroitinase ABC or chondroitinase AC
both in 100 mrs Tris-HC1, pH 7.5, 10 m calcium acetate, 2
mg/ml BSA or 100 milliunits of heparinase III in 50 mM
Tris-HCI, pH 7.4, 1 m calcium chloride, 5 m calcium
acetate. All samples also received 1 mi PMSF, 5 mrvi benza-
midine, 100 tg/ml soy bean trypsin inhibitor, 10 g/ml leupeptin
and 10 sg/ml antipain. Chondroitinase-containing mixtures
were incubated at 37°C for 1.5 hours, and heparinase containing
mixture at 22°C for 1.5 hours. At termination samples were
prepared for SDS-PAGE.
Immunofluorescence microscopy
After various treatment conditions, proximal tubule cells
were prepared for immunofluorescence studies. Cells were
fixed with 0.25% glutaraldehyde in phosphate buffered saline
(PBS), pH 7.3, for one hour at room temperature or overnight in
a refrigerator, then permeabilized with 0.1% Triton X-100 in
PBS for five minutes. Actin microfilaments were visualized by
staining with phalloidin conjugated to rhodamine diluted 1:30
(950 p1/plate) for 30 minutes at 37°C. Ten p1 of 90% glycerol was
then added. Preparations were examined with a Zeiss photomi-
croscope equipped for transmitted light and epifluorescence.
Quantitative morphometry
This process was accomplished by previously described
techniques [14]. In brief, two random fields were selected from
each culture plate. At lOOx magnification, 8 x 10 inch photo-
graphic print was made of the selected field. Using a computer
operator assisted morphometer (Woods Hole Educational As-
sociates, Woods Hole, Massachusetts, USA) and a Summa
graphics digitizing tablet, the area of field occupied by cells (A)
and that not occupied with cells (B) were measured. The
percent of the culture plate which was transformed after
TGF-131 addition, (T), was calculated at T(%) = B/(A + B).
3H-thymidine incorporation
The DNA synthetic response of cells to various agents was
monitored using 3H-thymidine incorporation. Confluent cul-
tures were made quiescent by the addition of fresh medium
containing no hydrocortisone or insulin. After 24 hours, xylo-
side (1 mM), galactosamine (2.5 mM) or cytocholasin B (0.4 ELM)
or D (0.02 tM), was added to the culture media. After an
additional six hours, TGF-f31 (10 ng/ml) or sham solution was
added. After 48 hours of TGF-/31 exposure, EGF (0.1 /.LM) was
added. 3H-thymidine was added to the cultures and the cells
were processed for 3H-thymidine incorporation 24 hours later
by methods previously reported [14].
Statistical methods
Statistical analysis was performed using Student's t-test.
Unless otherwise stated, the number of experiments refer to a
separate number of cultures. All results are represented as
mean SE.
Materials
All reagents used were of the highest grade commercially
available. All organic reagents were obtained from Sigma
Chemical Company (St. Louis, Missouri, USA) unless other-
wise indicated. Radioactive tracers were obtained from New
England Nuclear (Boston, Massachusetts, USA): (Methyl-3H)-
thymidine (2 Cilmmol), 35S-methionine (1139 Ci/mmol), 355
sulfate (748 jsCi/mmol). EGF (recombinant human) was ob-
tained from Amgen Biologicals (Thousand Oaks, California,
USA), TGF-/31 (porcine platelets) from R & D Systems (Min-
neapolis, Minnesota, USA). Rhodamine-conjugated phalloidin
was purchased from Molecular Probes (Junction City, Oregon,
USA). Polyclonal antibodies against fibronectin were obtained
as previously described [18].
Results
Characterization of TGF-f31 -induced proteoglycan synthesis
Biosynthetic labeling with 35S-sulfate of proteoglycans pro-
duced by primary rabbit renal proximal tubule cells under
control, quiescent, confluent conditions demonstrated that at
least two classes of proteoglycans were synthesized and se-
creted into the culture media (Fig. 1). One class was identified
as a broad band on SDS-PAGE centered at 220 kD and another
as a labeled band at the top of the lane due, most likely, to
restrictive entry into the gel from the large size of this molecule.
Treatment of cells with TGF-f31 for 48 hours increased the
quantity of secreted proteoglycans, as reflected by the in-
creased density of the proteoglycan bands on SDS-PAGE. In
three independent experiments, this increase in proteoglycan
production was approximately threefold. Exposure of quies-
cent, confluent cells in culture to the proteoglycan synthesis
inhibitor [20], 4-methylumbelliteryl-f3-D-xyloside (xyloside, 1
mM) 6 to 24 hours prior to TGF-/31 treatment diminished the
labeling of both classes of secreted proteoglycans both under
control and TGF-f31 stimulated conditions. Increased labeling
of small molecular weight molecules (less than 66 kD) was also
observed. These components are most likely glycosaminogly-
cans (GAG) due to the primary action of xyloside to compete
with the xylosylated core protein for GAG chain elongation,
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Fig. 1. Effect of TGF-131 on synthesis of proteoglycans secreted into
culture media by proximal tubule cells as demonstrated in this repre-
sentative experiment. Cell cultures were treated with various agents
and metabolically labeled with 35S-sulfate. Equal volumes of culture
media were analyzed by SDS-PAGE and fluorography. Lane 1, control;
Lane 2, TGF-/31; Lane 3, xyloside; Lane 4, xyloside and TGF-131; Lane
5, galactosamine; Lane 6, galactosamine and TGF-131.
thereby uncoupling proteoglycan synthesis [21]. Similarly, pre-
treatment of cells with galactosamine (2.5 mM), which acts as a
sink for uridine diphosphate (UDP) which is a necessary factor
for saccharide moieties to be utilized for proteoglycan synthesis
[221, also diminished proteoglycan synthesis under both control
and TGF-f31 treated conditions.
Assessment of 35S-sulfate labeling of proteoglycans incorpo-
rated into the extracellular matrix by extraction and parallel
analysis of the cell layer demonstrated that TGF-f31 increased
the accumulation within the cell layer of radiolabeled proteo-
glycans of similar size as those secreted into the culture media.
Xyloside and galactosamine were effective in diminishing the
TGF-J31 related increase in newly synthesized proteoglycans
incorporated into the cell layer (Fig. 2). Of note, the increases
in GAG labeling released into the cell supernatant was not
observed in the cell layer.
Ident(fication of proteoglycans by enzyme digestion
Digestion of the conditioned media after biosynthetic labeling
with 35S-sulfate with glycosaminoglycan-degrading enzymes
was accomplished to identify the type of proteoglycans pro-
duced under control and TGF-pl stimulated conditions [18, 19].
Treatment of cell supernatants with heparinase III degraded
Fig. 2. Effect of TGF-/31 on synthesis of proteoglycans incorporated
into the cell layer as demonstrated in this representative experiment.
Cell cultures were treated with various agents and metabolically labeled
with 35S-sulfate. Equal amounts of cellular extracts were analyzed by
SDS-PAGE and fluorography. Lane 1, control; Lane 2, TGF-131; Lane
3, xyloside; Lane 4, xyloside and TGF-/31; LaneS, galactosamine; Lane
6, galactosamine and TGF-/31.
virtually all 355-sulfate proteoglycans from both control and
TGF-/31 treated conditions (Fig. 3); the same effects were
observed with nitrous acid treatment. In contrast, treatment
with chondroitinase AC and chondroitinase ABC did not have
dramatic degradative effects on labeled proteoglycans under
both control and TGF-f31 stimulated conditions. These results
indicate that the proteoglycans produced by proximal tubule
cells and augmented by TGF-f31 are heparan sulfate proteogly-
cans.
Effect of TGF-f31 on fibronectin synthesis
Biosynthetic labeling with 35S-methionine of proximal tubule
cells was employed to label newly synthesized proteins. Com-
pared to control preparations, treatment with TGF-131 (10
ng/ml) for 48 hours resulted in increases in the radiolabeling of
several protein bands both in the cell medium and cell layer
(data not shown). Since TGF-/3l has been shown to increase the
synthesis of various extracellular matrix proteins, predomi-
nantly fibronectin [23], further experiments were done to deter-
mine whether TGF-f31 also stimulated fibronectin synthesis in
renal proximal tubule cells. Parallel immunoprecipitation exper-
iments with anti-fibronectin antibody followed by SDS-PAGE
were carried out on radiolabeled condition media from both
















Fig. 3. IdentUlcation of proteoglycans
regulated by TGF-'31 in proximal tubule cells
as demonstrated in this representative
experiment. Conditioned media containing
35S-sulfate labeled proteoglycans were
subjected to specific enzyme digestion.
Conditioned media were obtained from cells
treated (+) or not treated (—) with TGF-13l
for 48 hours. Conditioned media were treated
with various enzymes as specified (Hep III
represents heparinase III) then analyzed by
SDS-PAGE and fluorography.
control and TGF-f31 stimulated cells. As demonstrated in Fig-
ure 4, renal proximal tubule cells synthesized fibronectin under
control conditions; TGF-/31 treatment resulted in stimulation of
fibronectin production. Similar results were observed in the
extracted cell layer as well (data not shown). Of note, control
preparations using pre-immune serum did not demonstrate
precipitable product.
Effect of TGF-f31 on actin filament organization
As revealed by rhodamine-conjugated phalloidin staining in
Figure 5, proximal tubule cells under control culture conditions
contained both peripheral bands of actin near cell membranes
and randomly oriented cytoplasmic fibers, similar to other
epithelial cells [24, 25]. Treatment of cells with TGF-I.31 resulted
in higher ordered actin filament architecture which progressed
with time. As early as 8 to 12 hours after TGF-/31 (10 nglml)
addition to quiescent confluent monolayers of proximal tubule
cells, actin fibers coalesced into large bundles, or stress fibers,
with direct extension of these fiber formations from cell to cell,
indicating that these bundles share spatial information. By 24
hours, relatively intense staining of actin was observed at sites
of cellular aggregates where actin fibers were forming a tight
lattice network among cells. At 48 hours, the actin filaments
have organized into a three dimensional web supporting the
structure of the aggregate; and at 72 hours, clearly defined
adhesion plaques and stress fibers in cell surface protrusions
were evident. Both cytochalasin B (0.4 sM) and cytochalasin D
(0.02 /xM) treatment of cells resulted in disruption of microfila-
ments with localized aggregation (Figs. 5 C and D). Under
control conditions, cytochalasin treatment rapidly promoted
dense aggregation of actin filaments at the junction of cells, the
sites of fiber initiation and communication between cells. The
rearrangement of actin filaments into stress fibers and orches-
trated architectural arrays between cells induced by TGF-f31
was completely inhibited by cytochalasin B and D at 12 hours of
exposure.
Role of proteoglycans and actin in TGF-f31 promoted
phenotypic transformation
Previous reported experiments have demonstrated that
TGF-f31 induces a phenotypic transformation of monolayers of
renal proximal tubule cells into migratory, adhesive aggregates
of cells [14]. As demonstrated in Figure 6, this transformation,
as measured by quantitative morphometry, began approxi-
mately 12 hours following TGF-f31 exposure with completion at
72 hours. Since the current data demonstrate that TGF-/31
promotes synthesis of various extracellular matrix molecules,
including proteoglycans and fibronectin, and actin microfila-
ment rearrangement in renal proximal tubule cells, further
experiments utilizing quantitative morphometry were under-
taken to assess the effects of proteoglycan synthesis inhibition
and microfilament disruption on this TGF-f31 promoted trans-
formation. As seen in Figure 6, pretreatment of the cell mono-
layer with xyloside (1 mM) and galactosamine (2.5 mM), as
proteoglycan inhibitors, for 6 to 24 hours prior to TGF-f31 (10
ng/ml) resulted in a delayed and inhibitory transformation
response to TGF-f31. Since galactosamine inhibits proteoglycan
metabolism by acting as a UDP sink to limit the availability of
UDP as a necessary factor for GAG extension, uridine has been
previously shown to reverse the metabolic effects of galac-
tosamine [7]. In an additional set of experiments from those
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Fig. 4. Effect of TGF-/31 on fibronectin production by proximal tubule
cells. Equal volumes of conditioned media from control (lane 1) and
TGF-pl (lane 2) treated cells were immunoprecipitated with antisera to
fibronectin followed by SDS-PAGE and fluorography.
reported in Figure 6, uridine (5 or 15 mM) was added simulta-
neously with galactosamine to proximal tubule cells six hours
prior to TGF-J31 treatment to determine if this compound could
reverse the effect of galactosamine to inhibit TGF-f3l promoted
transformation. In this regard, uridine reversed the inhibitory
effect of galactosamine on TGF-131 alterations. At 72 hours, by
quantitative morphometry, TGF-f31 alone induced a 78 6%
transformation response; galactosamine pretreatment reduced
this TGF-pl effect to 21 1% (N = 3, P < 0.01 compared to
TGF-pl alone); simultaneous uridine and galactosamine treat-
ment resulted in a TGF-$1 transformation response of 44 5%
(N = 3, P < 0.02 compared to galactosamine + TGF-$1).
Pretreatment of cells with either cytochalasin B (0.4 M) or
cytochalasin D (0.02 jsM) retarded TGF-$l induced phenotypic
transformation with a magnitude effect greater than that ob-
served with proteoglycan inhibitors, as shown in Figure 6. Of
importance, no effect was observed with the fibronectin binding
site inhibitor [26], arg-gly-arp-ser (1 mglml, data not shown).
Influence of proteoglycan synthesis inhibitors and actin
microfilaments on DNA synthesis
Recent work has demonstrated a direct correlation between
TGF-pl induced phenotypic alteration and its antiproliferative
effect in proximal tubule cells [14], thereby suggesting that the
cellular elements responsible for this morphologic change may
also play a role in this antiproliferative effect. Since the present
data demonstrated a role for both proteoglycan synthesis and
actin rearrangement in TGF-131 's effect, further experiments
were undertaken to evaluate the influence of these factors on
DNA synthesis rates in proximal tubule cells. Pretreatment of
quiescent, confluent monolayers of cells with either xyloside (1
mM) or galactosamine (2.5 mM) for either 6 to 24 hours had little
effect on basal DNA synthesis rates, as assessed by 3H-
thymidine incorporation, but significantly inhibited the increase
in DNA synthesis rates promoted by EGF (0.1 LM), as depicted
in Figure 7. This inhibition did not appear to be due to increases
in the GAG, heparan sulfate, which may occur under these
conditions, since the addition of heparan sulfate (50 mM) did not
change the magnitude of EGF-induced 3H-thymidine incorpo-
ration in renal proximal tubule cells (data not shown), as has
been described in renal mesangial cells [27]. In contrast, pre-
treatment of monolayers with cytochalasin B (0.4 /.LM) had no
effect on either control or EGF-stimulated DNA synthetic rates
(Fig. 7). Similar results were seen with cytochalasin D (0.02
SM).
Since cytochalasin B retarded TGF-13l-induced phenotypic
transformation but did not inhibit EGF-promoted 3H-thymidine
incorporation, cytochalasin B could be used to further test the
relationship between TGF-pl mediated transformation and its
antiproliferative effect. As demonstrated in Figure 8, TGF-f31
addition to quiescent, confluent cells for 24 hours prior to EGF
treatment resulted in a significant inhibition of the increases in
3H-thymidine incorporation promoted by EGF. Pretreatment of
cells with cytochalasin B (0.4 avt) six hours prior to TGF-3l
addition, which attenuated the rate of TGF-f31 induced trans-
formation, however, significantly ameliorated the inhibitory
effect of TGF-/31 on EGF induced increases in 3H-thymidine
incorporation. Similar findings were also observed with cyto-
chalasin D (0.02 ILM).
Discussion
Transforming growth factor-beta (TGF-J3) is now considered
a critical cell regulatory protein with a wide spectrum of cellular
effects. This family of peptides has diverse influences on cell
growth, cell differentiation, and cell chemotaxis [1—3]. Accord-
ingly, TGF-f3 has been shown to be important in wound healing,
tissue remodeling and embryonic morphogenesis [8—12]. TGF-/3
has been generally viewed as a growth stimulatory factor for
mesenchymal cells and a growth inhibitory factor for epithelial
cells. Unlike most epithelia, renal tubule cells are mesodermally
derived, so that the effects of TGF-f3 on this cell may be
especially interesting. In this regard, recent work has shown
that TGF-/3 treatment of renal proximal tubule cells in primary
cultures inhibited both baseline and EGF-stimulated DNA
synthesis after 48 hours of exposure but enhanced EGF-
stimulated DNA synthesis at 24 hours [14]. Morphologic eval-
uation demonstrated that TGF-J31 promoted a dramatic pheno-
typic transformation of the epithelial monolayer with migration
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Fig. 5. Effect of TGF-1 on actin distribution in renal proximal tubule cells. Filamentous actin was visualized by staining with rhodamine-
phalloidin and indirect immunofluorescent microscopy. A. Monolayer of proximal tubule cells under control conditions. B. TGF-pl treatment for
12 hours, C. Cytochalasin D exposure for 2 hours. D. Simultaneous TGF-131 and cytochalasin D exposure for 12 hours. E. TGF-131 treatment for
24 hours. F. TGF-/3l treatment for 72 hours.
and adhesion of the cells to form solid clusters of adherent cells. DNA synthesis. Since many of the multiple actions of TGF-/31
Quantitative morphometry demonstrated that this transforma- are mediated through regulation of synthesis of extracellular
tion developed within 12 hours after TGF-/31 exposure, was matrix (ECM) components [17—231, these studies were under-
nearing completion after 48 to 72 hours of TGF-/3 treatment, taken to evaluate the influence of TGF-f31 on the synthesis of
and correlated to TGF-pl related inhibition of EGF-induced both proteoglycans and fibronectin, two key ECM molecules,
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Fig. 6. Effect of the proteoglycan inhibitors, (A) xyloside and (B)
galactosamine, and the actin microfilament disrupting agents, (C)
cytochalasin B and D, on the time course of TGF-/31 -induced
phenoiypic transformation. Symbols are: in panels A, B and C,
respectively, (A) is TGF-pl + xyloside, TGF-/31 + galactosamine,
and TGF-/3 + cytochalasin B or D; (0) TGF-/31. Proximal tubule
cells in culture were pretreated with xyloside then exposed to TGF-
10 20 30 40 50 60 70 80 1 at time Ofor 72 hours. The degree of transformation was assessedby quantitative morphometry. Data are expressed as mean SE; N
Time hours = 3 to 12 separate experiments for each data point. Error bars are





Fig. 7. Effect of proleoglycan synthesis inhibitors and actin microfila-
ment disruption on EGF-induced 3H-thymidine incorporation (s).
Pretreatment of tubule cells in culture with both xyloside (0) and
galactosamine (U) inhibited EGF promoted DNA synthesis; cytocha-
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and the role of these components in the functional effects of
TGF-f3l action on renal proximal tubule cells.
The present findings demonstrate that TGF-131 stimulated the
synthesis of both proteoglycans and fibronectin by renal prox-
imal tubule cells. Similar to a variety of other cells [231,
including glomerular epithelial cells [19], proximal tubule cells
synthesize fibronectin under basal conditions and this synthetic
rate is increased with TGF-J3l exposure. Unlike other cells,
including glomerular mesangial and glomerular epithelial cells,
in which TGF-pl promotes the synthesis of chondroitin/derma-
tan sulfate proteoglycans [11—14, 16—19], TGF-/31 stimulated the
production of two classes of heparan sulfate proteoglycans. The
synthesis of these proteoglycans appears to be important in the
phenotypic transformation of proximal tubule cells which is
promoted by TGF-/31. Two chemically dissimilar proteoglycan
synthesis inhibitors were utilized in this study to test the
functional role of proteoglycan synthesis on the effects of
0
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Fig. 8. Effect of actin microfilainent disruption on TGF-/31 and EGF
related changes in 3H-thymidine incorporation. Pretreatment of proxi-
mal tubule cells in culture with cytochalasin B prior to TGF-/3l
addition, at a dose which retarded TGF-131 induced transformation,
ameliorated the decrease in EGF promoted 3H-thymidine incorporation
induced by TGF-f31. *p < 0.01 compared to EGF alone; ** < 0.02
compared to EGF and TGF-/31, N = 6 for each condition.
TGF-/31 in these cells. Both xyloside and galactosamine were
used as proteoglycan synthesis inhibitors [20—22]. Xyloside
inhibits proteoglycan production by competing with xylosylated
core proteins for GAG elongation. The biosynthetic labeling of
proteoglycans with 35S-sulfate demonstrated this effect with a
decline in radiolabeling of newly synthesized proteoglycans
both in the supernatant and cell layer and an accumulation in
the supernatant of low molecular weight GAGs. Galactosamine
inhibits proteoglycan synthesis via a different mechanism by
acting as a sink for UDP which is a necessary factor for
saccharide incorporation into proteoglycans. Similar to xylo-
side, galactosamine was shown to inhibit TGF-f31 stimulated
production of proteoglycans. This inhibitory effect was accom-
panied with attenuation of the TGF-/31-promoted phenotypic
transformation of proximal tubule cells, as assessed by quanti-
tative morphometry. Further support for a role for proteogly-
cans in this transformation response is the observation that
simultaneous administration of uridine with galactosamine an-
tagonized the effect of galactosamine on TGF-/31 transforming
effects on the cells. This delay and inhibitory effects of these
compounds suggest that proteoglycan synthesis is necessary for
this transformation process. The fact that the inhibition is not
complete suggests that other cellular elements are likely critical
in this process.
Since this phenotypic change promoted by TGF-/31 on renal
proximal tubule cells was characterized by both cellular aggre-
gation and cellular migration, this change was also likely
dependent upon cytoskeleton rearrangements. In this regard,
assessment of TGF-131 influences on actin microfilament struc-
ture in these cells with the utilization of rhodamine-conjugated
phalloidin staining and immunofluorescent microscopy demon-
strated that TGF-/31 provoked a dramatic rearrangement of
actin microfilaments. Similar to other epithelial cells [24, 25],
renal tubule cells in monolayer possess peripheral bands of
actin near cell membranes and randomly oriented cytoplasmic
fibers. Within a few hours following TGF-/31 treatment, actin
fibers coalesced into stress fibers with direct linkages from cell
to cell. Later these fibers were clearly seen to terminate at
clearly-defined adhesion plaques. These effects of TGF-f31 on
actin have been previously observed in other cell systems [28,
29]. The importance of this actin microfilament rearrangement
in the TGF-/31 promoted phenotypic alteration was demon-
strated with the use of cytochalasin B or D. These actin
microfilament disrupting agents [30, 31] clearly attenuated
stress fiber formation promoted by TGF-13l and inhibited the
TGF-pl-induced morphologic transformation of these cells.
These results demonstrate the importance of both proteogly-
can synthesis and cytoskeleton rearrangement in the induction
of the adhesive migratory response of these mesenchymally-
derived epithelial cells promoted by TGF-f3l. This response
may be important in the cell biology of tissue modeling during
wound repair and embryogenesis [32, 33].
Besides inducing a dramatic phenotypic transformation in
renal epithelial cells, TGF-f31 has also been shown to influence
the cell proliferative response of these renal tubule cells under
both basal and mitogenic stimulation [13, 14]. This response has
displayed both an early phase of enhancing cell proliferation
and a later phase of inhibiting cell proliferation in renal tubule
cells. Furthermore, the anti-proliferative effect of TGF-f31 on
these cells was directly correlative to the phenotypic transfor-
mation promoted by this regulatory peptide, suggesting that the
cellular elements responsible for this transformation may also
be important in this anti-proliferative effect. In this regard,
further experiments were carried out to assess the role of
proteoglycans and cytoskeleton on the effect of both EGF and
TGF-/31 on DNA synthesis in these cells. These results clearly
demonstrate that proteoglycan synthesis is required to allow for
a maximal proliferative response of these epithelial cells to the
potent mitogen, EGF. This observation provides further evi-
dence for a role for extracellular matrix molecules to regulate
cell growth rates to various growth factors. In fact, TGF-j31 has
been previously shown to potentiate the mitogenic effect of
EGF on renal tubule cells during short exposure times [14]. The
present results, which demonstrate that TGF-/3l promotes
proteoglycan production by tubule cells and that proteoglycan
synthesis inhibition attenuates EGF effects on cell proliferation,
suggest that TGF-/31-induced proteoglycan production may be
important in its early effects to stimulate EGF induced mito-
genesis. Further experiments are required to determine whether
the mechanism of this effect is due to changes in the affinity or
number of cell surface receptors to EGF or due to alterations in
the intracellular transduction process.
In contrast, actin microfilament disruption with cytochalasin
B or D did not change the rate of DNA synthesis of these cells
in response to EGF but did attenuate the anti-proliferative
effect of TGF-/31 of these cells to EGF. Recent evidence has
suggested that the mechanism of the anti-proliferative effect of
TGF-13 relates to influences on the proteins encoded by the
c-myc and retinoblastoma genes [34, 35], although dissociation
between myc-gene expression and growth inhibition by TGF-f31
in some cells has been reported [36, 37]. The current results
provide a suggestion that an intact system for actin microfila-
ment assembly is also required for the appropriate transduction
of the TGF-j31 signal to promote a full anti-proliferative effect.
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promoted phenotypic transformation of these cells and simul-
taneously attenuated the inhibitory effect of TGF-/3l on EGF-
stimulated DNA synthesis. The role of the cytoskeleton in the
transduction of peptide hormone signals is just beginning to be
appreciated [38, 39].
In summary, TGF-/31 promotes the production of heparan
sulfate proteoglycans and fibronectin and also promotes a
well-defined progression of actin microfilament aggregation in
renal proximal tubule cells in primary culture. Both the produc-
tion of proteoglycans and the higher ordered structure of the
cytoskeleton is instrumental in the adhesive, migratory re-
sponse of these cells to TGF-13l as well as the DNA synthesis
rate responses to both EGF, as a cell growth promoter, and
TGF-/31, as a growth inhibitor. These cellular processes are
likely important in the effect of TGF-/31 to influence tissue
modeling during tissue repair following injury and morphogen-
esis during embryonic development.
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